BTG

Genetically Engineered Drugs

Health Tech & Life Sciences
Acquired by Ferring Pharmaceuticals on Jan, 2005

Company Overview

Snapshot

Founded in September 1980, BTG operates with 201–500 employees. The company was acquired by Ferring Pharmaceuticals in January 2005, marking a significant milestone in its journey as a biopharmaceutical services provider.

Business overview

BTG (Bio-Technology General Israel) is an integrated biopharmaceutical services company specializing in the development and manufacturing of healthcare products derived from genetic engineering and biotechnology processes. Its core products include Biolon, an injectable system for ophthalmic surgeries, Euflexxa for osteoarthritis knee pain relief, and recombinant human growth hormone (somatropin for injection or hGH) for treating growth hormone deficiency and Turner syndrome. The company serves the health tech and life sciences sectors, operating within the biopharmaceutical and biotechnology categories.

Strategic signal

In September 2023, BTG articulated a vision for Israel to become a global leader in biological GMP production, signaling its strategic intent to influence national biotechnology manufacturing capabilities. This highlights BTG's ongoing commitment to advancing the biopharmaceutical industry beyond its product portfolio, positioning it as a key player in shaping the future of biotech production within the region.

Company Intelligence Q&A

When was BTG acquired?
BTG was acquired by Ferring Pharmaceuticals in January 2005.
What is BTG's vision for Israel's biotechnology sector?
In September 2023, BTG outlined its vision for Israel to become a world leader in biological GMP (Good Manufacturing Practice) production.
What is Biolon?
Biolon, first introduced in 1993, is an injectable system containing 1% fermentation-derived sodium hyaluronate (NaHA) used as a viscoelastic aid in cataract and other ophthalmic surgeries.
What is Euflexxa used for?
Euflexxa is a treatment designed to help relieve knee pain caused by osteoarthritis (OA), utilizing 1% fermentation-derived sodium hyaluronate for intra-articular injection into the knee.
When did BTG's recombinant human growth hormone receive regulatory approval?
BTG's recombinant human growth hormone (somatropin for injection or hGH), developed in the 1980s, first gained regulatory approval in 1988.

External links